Carmot Therapeutics Inc., a small-molecule lead-identification specialist and partner of Amgen Inc. since 2014, is extending its work for the Thousand Oaks, Calif.-based drugmaker to Parkinson's disease (PD) and other selected areas in a new multiyear deal. Clinical development, manufacturing and commercialization of any resulting molecules will be Amgen's job, while Carmot will receive an up-front payment of undisclosed value, research support and, potentially, milestone payments worth more than $240 million.